Board of Directors

William P. Forbes, Pharm.D., Founder & President and Chief Executive Officer

As the Founder & President, CEO of Vivelix Pharmaceuticals, Bill brings over 25 years of acknowledged, executive leadership experience and skills to Vivelix Pharmaceuticals.

Prior to founding Vivelix, Bill served as President, Medical, Research & Development and Chief Development Officer of Salix Pharmaceuticals until its sale to Valeant Pharmaceuticals in 2015.

As a corporate officer and head of Medical and R&D his responsibilities included areas of corporate communication, governance, compliance, planning, operations, strategy and management. During his tenure at Salix, Bill successfully guided 12 FDA approvals which contributed to the tremendous increase in value of the company over this time with a market capitalization of ~$500 M in 2005 to ~$11 B when it was acquired in April 2015.

Prior to Salix, Bill served as Vice President of Clinical Development and Regulatory Affairs of Metabasis (2002-2004) and in increasing positions of responsibility at Otsuka (1991-2002) and Glaxo (1989-1991).

During his diverse career, Bill has contributed to the approval of numerous marketing applications by health authorities including sNDAs and NDAs for: XIFAXAN550® (HE in CLD 2010, IBS 2015), RELISTOR® (Subcutaneous, OIC 2014; Oral, OIC 2016), RUCONEST® (HAE 2015), UCERIS® RECTAL FOAM (Distal UC 2015), FULYZAQ® (HIV-associated Diarrhea, 2012), GIAZO® (Acute UC, 2012), METOZOLV ODT® (Gastroparesis, 2009), APRISO® (Maintenance of Remission in UC, 2008), OSMOPREP® and MOVIPREP® (Bowel cleansing for colonoscopy, both 2006), COLAZAL® (Pediatric use in Acute UC, 2005), PLETAL® (Intermittent Claudication in PAD, 1999).

Bill received his Doctor of Pharmacy at Creighton University in 1987, where he was also a Cardiovascular Research Fellow and Clinical Research Fellow (1987-1989). As an experienced researcher, Bill has authored or co-authored over 48 published manuscripts.

Srini Akkaraju, M.D., Ph.D., Founder & Executive Chairman

Srini Akkaraju, M.D., Ph.D., previously had been a Senior Advisor and General Partner at Sofinnova Ventures from 2013 to 2016. Other appointments and positions held by Dr. Akkaraju include: Managing Director and Lead of West Coast Biopharmaceuticals Practice at New Leaf Venture Partners (2009-2013); co-founded Panorama Capital and was its Managing Director (2006-2008); Partner, Healthcare Group at J.P. Morgan Partners, LLC , where he was responsible for leading venture investing in biotech companies (2001-2006); Business and Corporate Development Group at Genentech, Inc. and served as its Senior Manager, where he was responsible for worldwide partnering activities including technology access deals, in-licensing of early and late-stage therapeutics, and out-licensing of Genentech development projects (1998-2001); Founding Member at BioStreet; and various board positions at numerous pharmaceutical companies including Versartis, Principia Biopharma, Pharmos, Karus, Ophthotech, aTyr, Intercept, Seattle Genetics, Barrier, Presidio, Phenomix, Synageva, ZS, Piramed, Itero, Microscience, Vela, BioStreet.com, Eyetech, Oldtech, Amarin and Pharmos. Dr. Akkaraju holds an M.D. and a Ph.D. in Immunology from Stanford University, Stanford School of Medicine and a B.A. in Biochemistry and Computer Science from Rice University.

Stephen Biggar, M.D., Ph.D., Director

Stephen R. Biggar, M.D., Ph.D., is a Partner at Baker Bros. Advisors LP, a registered investment adviser focused on long-term investments in life sciences companies. Dr. Biggar joined Baker Bros. Advisors LP in 2000. Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University, Stanford School of Medicine and received a B.S. in Genetics from the University of Rochester.

Sara Brownstein, Director

Sara Brownstein is a Vice President at Baker Bros. Advisors LP, a registered investment adviser focused on long-term investments in life sciences companies. Prior to joining Baker Brothers in 2011, Ms. Brownstein was an Analyst at Goldman, Sachs & Co. Ms. Brownstein holds a BAS in Biomedical Science (School of Engineering and Applied Science) and a B.S. in Economics (Wharton School) from the University of Pennsylvania.